Procyon Advisors LLC Purchases 760 Shares of Eli Lilly and Company (NYSE:LLY)

Posted by Defense World Staff on Mar 27th, 2023

Eli Lilly and logo Procyon Advisors LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Get Rating) by 57.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,094 shares of the company’s stock after purchasing an additional 760 shares during the period. Procyon Advisors LLC’s holdings in Eli Lilly and were worth $766,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in LLY. Price T Rowe Associates Inc. MD raised its stake in shares of Eli Lilly and by 21.6% during the third quarter. Price T Rowe Associates Inc. MD now owns 24,839,322 shares of the company’s stock valued at $8,048,338,000 after acquiring an additional 4,412,664 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Eli Lilly and by 54.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,311,713 shares of the company’s stock valued at $948,375,000 after buying an additional 1,172,504 shares during the period. Vanguard Group Inc. increased its holdings in Eli Lilly and by 1.4% during the third quarter. Vanguard Group Inc. now owns 72,588,317 shares of the company’s stock valued at $23,471,432,000 after buying an additional 996,990 shares during the period. Renaissance Technologies LLC increased its holdings in Eli Lilly and by 153.1% during the third quarter. Renaissance Technologies LLC now owns 1,014,647 shares of the company’s stock valued at $328,086,000 after buying an additional 613,764 shares during the period. Finally, First Trust Advisors LP increased its holdings in Eli Lilly and by 229.5% during the third quarter. First Trust Advisors LP now owns 729,008 shares of the company’s stock valued at $235,724,000 after buying an additional 507,733 shares during the period. Institutional investors own 82.13% of the company’s stock.

Eli Lilly and Stock Up 1.0 %

LLY stock opened at $336.13 on Monday. Eli Lilly and Company has a 52 week low of $276.83 and a 52 week high of $384.44. The stock has a market capitalization of $319.42 billion, a P/E ratio of 48.71, a P/E/G ratio of 1.92 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.05 and a debt-to-equity ratio of 1.37. The firm has a 50-day simple moving average of $333.48 and a 200-day simple moving average of $342.64.

Eli Lilly and (NYSE:LLY – Get Rating) last announced its quarterly earnings data on Thursday, February 2nd. The company reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.26. Eli Lilly and had a net margin of 21.88% and a return on equity of 73.61%. The company had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $7.39 billion. During the same quarter in the prior year, the company earned $2.49 EPS. Eli Lilly and’s revenue was down 8.7% compared to the same quarter last year. Equities analysts forecast that Eli Lilly and Company will post 8.49 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and

In other news, EVP Anne E. White sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, February 13th. The shares were sold at an average price of $346.47, for a total value of $866,175.00. Following the transaction, the executive vice president now directly owns 57,926 shares in the company, valued at approximately $20,069,621.22. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on LLY shares. Cowen lifted their price target on shares of Eli Lilly and from $390.00 to $430.00 and gave the stock an “outperform” rating in a report on Monday, December 5th. Barclays boosted their price objective on shares of Eli Lilly and from $395.00 to $400.00 and gave the company an “overweight” rating in a report on Tuesday, January 3rd. Societe Generale lowered shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $278.00 price objective on the stock. in a report on Wednesday, February 15th. Guggenheim boosted their price objective on shares of Eli Lilly and from $399.00 to $401.00 and gave the company a “buy” rating in a report on Wednesday, December 7th. Finally, UBS Group dropped their price objective on shares of Eli Lilly and from $428.00 to $420.00 and set a “buy” rating on the stock in a report on Thursday, December 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $382.05.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.